Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two Patents, Five Patent Applications Related to RNAi

Premium
Title: Inhibitors of Ribonucleotide Reductase Subunit 2 and Uses Thereof
 
Number: 7,427,605
 
Filed: March 31, 2006
 
Lead Inventor: Mark Davis, Calando Pharmaceuticals
 
The patent, its abstract states, “relates to inhibitors of ribonucleotide reductase subunit 2, and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.”
 

 
Title: High-Throughput Methods for Identifying Gene Function Using Lentiviral Vectors
 
Number: 7,427,474
 
Filed: July 25, 2003
 
Inventor: Boro Dropulic, Virxsys
 
The invention, the patent abstract states, “relates to methods and compositions for the efficient identification of one or more functionalities of a product encoded by a nucleic acid sequence of interest. The methods utilize the abilities to over- and/or under-express the product in a cell, as well as the combination of these results, to permit the identification of at least one of the product's cellular or in vivo functionality.”
 

 
Title: siRNA Targeting Ribonucleotide Reductase M2 Polypeptide
 
Number: 20080227967
 
Filed: June 13, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM2.”
 

 
Title: Cell-Based RNA Interference and Related Methods and Compositions
 
Number: 20080226553
 
Filed: Sept. 29, 2003 PCT Filed: Sept. 29, 2003
 
Lead Inventor: Scott Lowe, Cold Spring Harbor Laboratory
 
The invention claims, among other things, “methods for performing RNA interference in stem cells and methods for using stem cells in vivo,” the patent application’s abstract states.
 

 
Title: Method for Identification of Polynucleotides Capable of Cleaving Target mRNA Sequences
 
Number: 20080227103
 
Filed: Feb. 19, 2008
 
Lead Inventor: John Sullivan, University at Buffalo, State University of New York
 
According to the patent application’s abstract, the invention comprises “methods for identifying a polynucleotide that can reduce the level of a target mRNA. The method can be performed by providing cells that express an RNA polynucleotide that contains a target mRNA sequence, an internal ribosome entry sequence, and a sequence encoding a secreted reporter protein; introducing to the cells a test polynucleotide, and measuring activity of the secreted reporter protein.”
The abstract adds that “a reduction in secreted reporter protein activity relative to a control cell into which the test polynucleotide has not been introduced is indicative that the test polynucleotide is capable of reducing the level of the target mRNA in the cells. The method is adaptable for high-throughput screening methods and is suited for identifying polynucleotides that can catalyze cleavage of target mRNA and/or act on target mRNA through and antisense or RNAi mechanism.”
 

 
Title: Method for Treating and Preventing Ischemia Reperfusion Injury Using RNA Interfering Agent
 
Number: 20080227733
 
Filed: Nov. 1, 2004 PCT Filed: Nov. 1, 2004
 
Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)
 
The invention, the patent application’s abstract states, is based, at least in part, “on the discovery of methods useful in the modulation … of gene expression or protein activity. … In particular, the … invention is based on novel RNA interfering agents [capable of reducing] apoptosis-related gene expression or cytokine expression in cells. Inhibition of apoptosis-related gene expression or protein activity or cytokine gene expression or protein activity … inhibits ischemia-reperfusion injury.”
 

 
Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression
 
Number: 20080229456
 
Filed: Oct. 10, 2006
 
Lead Inventor: Shihshieh Huang, Monsanto
 
The invention, the patent application’s abstract states, “provides molecular constructs … including constructs including heterologous miRNA recognition sites; constructs for gene suppression including a gene-suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence; constructs containing engineered miRNA or miRNA precursors; and constructs for [suppressing] production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use.”
 
The abstract adds that the invention “further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.